ERAS Erasca Inc: Earnings per share for the trailing year

Erasca Inc (ERAS) - corporate logo

The market trend visualized in monetary format on GURU.Markets shows the EPS of Erasca, Inc. (ERAS) at -120.60. The market is currently awaiting the results of phase two trials for melanoma drugs, while R&D costs still exceed revenues. The business focuses on developing targeted therapies to block RAS/MAPK pathways, seeking collaborations with industry behemoths. The team consists of leading biologists motivated by stock options.

Erasca Corp (ERAS): Net earnings per share (EPS TTM) from 02/11/2024 to 11/14/2026

Erasca Corp - analytical breakdowns and key metrics (ERAS)

- current quotes and average value forecast:
Stock Price erasca.com|ERAS - Price Target Chart
- company stock capitalization data:
Market Value Erasca Inc|ERAS - Enterprise Value
- issuer book value statistics:
Net Asset Value per Share Erasca|ERAS - Book Capitalization|Market-to-Book Ratio erasca.com|ERAS - Aggregate Company Assets
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Erasca, Inc.|ERAS - Long-Term Debt to Capital|Short-Term Debt to Capital Erasca Oncology|ERAS - Company Debts|Debts to Net Assets Erasca Inc|ERAS - Company Long-Term Debts|Company Current Liabilities Erasca|Quick Ratio erasca.com
- net income and valuation ratios data:
ERAS - Net Income|Expected Net Income Erasca, Inc.|ERAS - P/E Multiple|Market Cap to Projected Earnings Erasca Inc|ERAS - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Erasca Inc|ERAS - Operating profit EBITDA|Net earnings per share for the last 12 months Erasca|ERAS - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months erasca.com|ERAS - Earnings growth in current year|Expected net earnings per share growth next year Erasca, Inc.
- sales and revenue indicators:
ERAS - Company Revenue|Company Future Revenue erasca.com|ERAS - P/S Multiple|Forward P/S Multiple Erasca Inc
Initial company analysis:ERAS (erasca.com)
Product sample of Erasca Corp

This indicator captures the percentage change in earnings per share over a rolling twelve-month period. It allows for an assessment of the scaling rate of profitability, preventing the erroneous extrapolation of temporary peaks. By analyzing the year-over-year EPS trend (over 12 months), an investor determines the sustainability of the business. For Erasca, Inc. (ERAS), such volatility reflects the costs of implementing green synthesis and ethical compliance in oncology.

Competitor analysis for Erasca, Inc.

ONC - Net earnings per share (EPS TTM)|Halozyme (HALO) - Earnings per share for the last twelve months|Revolution Medicines Inc - Earnings per share for the trailing year|AAPG (Ascentage) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CG Oncology Therapeutics CGON|Net earnings per share (EPS TTM) URGN|BCAX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Personalis PSNL|Earnings per share for the trailing year DCTH|YmAbs - Net earnings per share (EPS TTM)|AURA - Net earnings per share (EPS TTM)|candeltx.com (CADL) - Earnings per share for the last twelve months|ARAY - Net earnings per share for the last four quarters|SLS (SELLAS Life Sciences Group, Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Actuate Therapeutics Inc. (ACTU)|Net earnings per share (EPS TTM) CTOR|Net earnings per share (EPS TTM) tuhurabio.com (HURA)|Protara Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year FATE|Aadi Bio - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters TScan Therapeutics TCRX|championsoncology.com (CSBR) - Earnings per share for the last twelve months|Earnings per share for the last 12 months XBIT|CVM (CEL-SCI Corp.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months ostherapies.com (OSTX)|Net earnings per share for the last 12 months RADX (Radiopharm Theranostics Limited)|Net earnings per share for the last four quarters artivabio.com|Net earnings per share (EPS TTM) ANL (Adlai Nortye)|Veru Corporation (VERU) - Net earnings per one share for the last twelve months|TPST - Earnings per share for the last twelve months|Earnings per share for the trailing year XLO (Xilio Therapeutics, Inc.)|RENB: Net earnings per share (EPS TTM)|Mural Oncology (MURA) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Kairos Pharma Limited|OnKure (OKUR) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) GDTC|Net earnings per share for the last 12 months curis.com CRIS|Net earnings per share (EPS TTM) APLM (Apollomics)|Net earnings per share (EPS TTM) Tharimmune Inc THAR|ADVB - Earnings per share for the last twelve months|GNPX (Genprex Inc) - Earnings per share for the last 12 months|CLDI: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Sunshine Biopharma Inc.|XBIO (Xenetic Biosciences Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Salarius Pharmaceuticals Inc SLRX|Earnings per share for the last twelve months Purple Biotech Corp (PPBT)|AONC (aoncology.com) - Earnings per share for the trailing year|BeiGene, Ltd. - Net earnings per share for the last 12 months|Earnings per share for the trailing year CKPT|Elevation Oncology, Inc. - Net earnings per share (EPS TTM)|iCAD, Inc. (ICAD) - Net earnings per share for the last 12 months|IKNA (ikenaoncology.com) - Net earnings per share for the last 12 months|Notable Labs Corp (NTBL) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Viracta Therapeutics Inc.|MOR: Earnings per share for the trailing year|Net earnings per share (EPS TTM) NAYA|AAPGV - Net earnings per one share for the last twelve months